Early Pandemic Evaluation and Enhanced Surveillance of the coronavirus COVID-19 (EAVE II)
Not Applicable
Completed
- Conditions
- COVID-19 (SARS-CoV-2 infection)Infections and Infestations
- Registration Number
- ISRCTN40292537
- Lead Sponsor
- Academic and Clinical Centre Office for Research and Development (ACCORD) (UK)
- Brief Summary
2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/32565483/ protocol published at: 2021 Preprint results in http://dx.doi.org/10.2139/ssrn.3789264 non-peer-reviewed results (added 23/03/2021) 2022 Results article in https://doi.org/10.1016/S0140-6736(21)00677-2 (added 26/05/2022)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 5400000
Inclusion Criteria
All (anonymised) patient data will be collected
Exclusion Criteria
Does not meet inclusion criteria
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> 1. Laboratory confirmed SARS-CoV-2 measured using virological/serological tests between baseline and 9 months<br> 2. Serum from blood samples taken from biochemistry tests (or rapid antibody tests if available) will be used to determine exposure to SARS-CoV-2 infection by the presence of antibodies between baseline and 9 months<br> 3. SARS-CoV-2 infection-related clinical outcomes including general practice, COVID-19 centres and out-of-hours consultations, hospital admissions including secondary bacterial infections and multidrug-resistant bacteria associated with these infections, emergency admissions, out of hours consultations, and deaths between baseline and 9 months<br>
- Secondary Outcome Measures
Name Time Method <br> 1. Vaccine uptake proportions measured using primary care practice and hospital data between baseline and 18 months<br> 2. Prevention and reduction of SARS-CoV-2 infection-related general practice consultations, hospital admissions including secondary bacterial infections, emergency admissions, out of hours consultations and deaths due to therapies, vaccines, and antimicrobials between baseline and 18 months<br> 3. Adverse events related to therapies, for example, vaccine, antimicrobial administration, or other therapies measured using participant data between baseline and 18 months<br>